Results- The Pdcd10 <sup>+/</sup><sup>-</sup> Trp53 <sup>-/</sup><sup>-</sup> /Msh2 <sup>-/</sup><sup>-</sup> models showed a mean CCM lesion burden per mouse reduction from 0.0091 in placebos to 0.0042 ( P=0.027) by fasudil, and to 0.0047 ( P=0.025) by atorvastatin treatment, but was not changed significantly by simvastatin.